免疫功能正常患者的导管相关血流感染：一例病例报告及文献综述
catheter-related bloodstream infection in an immunocompetent patient: A case report and review of the literature.
作者信息
Turock Julia S, Matysiak Match Colette J, Adachi Kristina, Nielsen-Saines Karin, Yang Shangxin, Malhotra Sanchi
机构信息
University of California Los Angeles, Department of Pediatrics, Division of Hospital Medicine, Los Angeles, CA, USA.
University of California Los Angeles, Department of Pathology and Laboratory Medicine, Los Angeles, CA, USA.
出版信息
IDCases. 2024 Aug 3;37:e02051. doi: 10.1016/j.idcr.2024.e02051. eCollection 2024.
BACKGROUND
is an emerging rapidly growing mycobacteria (RGM) species that has been rarely reported to cause human disease. RGM catheter-related bloodstream infections (CRBSI) are often challenging to treat given the need for line removal, variable species-dependent antimicrobial susceptibility, combination antimicrobial treatment, and historically longer courses of antibiotics.
CASE PRESENTATION
We present a case of an immunocompetent pediatric patient with severe hemophilia B and CRBSI. While the patient's hemophilia B precluded a standard line holiday, he successfully cleared his infection with two line exchanges followed by two weeks of antibiotics.
CONCLUSIONS
RGM, including emerging species , may be considered in patients with an indolent presentation of CRBSI. Our case suggests source control with shorter courses of antimicrobials can be successful.
背景
是一种新兴的快速生长分枝杆菌（RGM）物种，很少有报道称其会引发人类疾病。鉴于需要拔除导管、不同物种对抗菌药物的敏感性各异、联合抗菌治疗以及历来较长疗程的抗生素使用，RGM导管相关血流感染（CRBSI）的治疗往往具有挑战性。
病例报告
我们报告一例患有严重B型血友病且发生CRBSI的免疫功能正常的儿科患者。虽然该患者的B型血友病使标准的导管停用不可行，但他通过两次更换导管并随后使用两周抗生素成功清除了感染。
结论
对于表现为隐匿性CRBSI的患者，可能需要考虑包括新兴物种在内的RGM。我们的病例表明，采用较短疗程抗菌药物进行源头控制可能会取得成功。
Zotero 插件